Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT6 | P42226 | 8/20 | 0.55 |
| ▸ | CDK4 | P11802 | 3/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.45 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.44 |
| ▸ | CCND1 | P24385 | 2/20 | 0.44 |
| ▸ | CCND2 | P30279 | 2/20 | 0.44 |
| ▸ | CCND3 | P30281 | 2/20 | 0.44 |
| ▸ | WEE1 | P30291 | 1/20 | 0.43 |
| ▸ | IGF1R | P08069 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 2/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.41 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3713891 | 0.89 | STAT6 (0.52) | STAT6CDK4AURKARPS6KA3TBK1 | |
| SCHEMBL3790571 | 0.89 | STAT6 (0.68) | STAT6CDK4AURKARPS6KA3CCND1 | |
| SCHEMBL3717362 | 0.86 | STAT6 (0.53) | STAT6CDK4AURKARPS6KA3TBK1 | |
| SCHEMBL3716704 | 0.86 | STAT6 (0.49) | STAT6CDK4AURKARPS6KA3TBK1 | |
| Cyclohexane SCHEMBL15163521 | 0.84 | TBK1 (0.54) | STAT6CDK4AURKATBK1CCND1 | |
| Cyclopropane SCHEMBL15163077 | 0.84 | TBK1 (0.54) | STAT6CDK4AURKATBK1CCND1 | |
| Cyclopentane SCHEMBL15163254 | 0.84 | TBK1 (0.54) | STAT6CDK4AURKATBK1CCND1 | |
| SCHEMBL15163339 | 0.84 | TBK1 (0.54) | STAT6CDK4AURKATBK1CCND1 | |
| SCHEMBL1285324 | 0.83 | TBK1 (0.64) | STAT6CDK4AURKATBK1JAK3 | |
| SCHEMBL3721132 | 0.83 | WEE1 (0.46) | STAT6CDK4AURKATBK1CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2403853-B1 | PYRROLOPYRIMIDINES USED AS KINASE INHIBITORS | MEDICAL RES COUNCIL TECHNOLOGY (GB) | 2013-08-14 | — | — | EP | claimed |
| WO-2010100431-A1 | PYRROLOPYRIMIDINES USED AS KINASE INHIBITORS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-09-10 | — | — | WO | claimed |
| EP-2403853-B1 | PYRROLOPYRIMIDINES USED AS KINASE INHIBITORS | MEDICAL RES COUNCIL TECHNOLOGY (GB) | 2013-08-14 | — | — | EP | disclosed |
| US-20120088753-A1 | PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2012-04-12 | — | — | US | disclosed |
| US-20120088753-A1 | PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2012-04-12 | — | — | US | disclosed |
| US-20120088753-A1 | PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2012-04-12 | — | — | US | disclosed |
| EP-2403853-A1 | PYRROLOPYRIMIDINES USED AS KINASE INHIBITORS | Medical Research Council Technology (GB) | 2012-01-11 | — | — | EP | disclosed |
| WO-2010100431-A1 | PYRROLOPYRIMIDINES USED AS KINASE INHIBITORS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-09-10 | — | — | WO | disclosed |
| WO-2010100431-A1 | PYRROLOPYRIMIDINES USED AS KINASE INHIBITORS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088753-A1 | PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS | MARK3, MAPK8, CDK8 | STAT6 446/4885CDK4 85/4885AURKA 474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.